2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

ELIXIA ® and BIOELIXIA ® 16 The year started with great expectation with the international expansion culminating in a launch in Europe through Boots as part of the Latest Finds category. Retail globally has been subdued and this, together with widespread discounting in cosmetics, created a challenging environment. The areas where sales were maintained at a satisfactory level were on line and TVSN. This reflects, in part, that where sales people have the opportunity to promote the science behind the product we have the best response from consumers. Phosphagenics undertook an extensive review of the Elixia ® and BioElixia ® business and made some personnel changes including the appointment of the well credentialed and highly regarded Greg Moses. His background and experience covers all aspects of the business from selling through retail outlets and the growing areas of on-line and TV shopping. We are in the process of increasing our on-line capability which we are utilising in our launch into the US. The key is to translate the anecdotal evidence of a high level of customer satisfaction. With a focused and dynamic strategy in place we are looking at more targeted and effective promotional activity with our existing retailers and rapid expansion into the broader Australian retail pharmacy channel. Additional refinement and consistencies across packaging, logistics and supplier relationships for improved cost of goods and efficiencies will underpin the strategy. Driving on-line retail sales is a major focus and the launch of a US e-commerce site in the first half will additionally support sales expansion and brand communication globally. The introduction of a stretch mark diminishing product in 2013 will further support the targeted body solutions that Bio Elixia ® offers. We also continue to strengthen our expertise with contract manufacturing and will deliver products under license to customers in the US like GNC (Global Nutrition Company) throughout 2013. In the last few months since Greg’s appointment the sales have been more satisfactory, at a level reflecting a good improvement over the corresponding months in the previous year. As the strategy unfolds and repositions the brands we are expecting that the next six months will see us consolidate at this higher level before further progress in the second half. PHOSPHAGENICS ANNUAL REPORT 2012
BEAUTY IS MORE THAN SKIN DEEP 17 ELIXIA ® AND BIOELIXIA ®
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15 and 16: 13 is branded as Butrans or Norspan
Page 17: Personal Care ASHLAND INC (FORMERLY
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49 and 50: Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70:
Consolidated statement of changes i
Page 71 and 72:
Notes to the consolidated fi nancia
Page 73 and 74:
Application date of standard Impact
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?